Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide

Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide

13 February 2018

The extraordinary contribution of Australia’s most distinguished clinicians and researchers in the field of melanoma is being celebrated today at a symposium hosted by Melanoma Institute Australia (MIA).

More than 350 clinicians and researchers have gathered at The Ultimate Melanoma Masterclass in Sydney to learn from the luminaries as well as hear a comprehensive review on the latest advances in research and clinical management of melanoma.

Professors John Thompson AO, Richard Kefford AM, Stan McCarthy AO, Peter Hersey and Roger Uren have transformed the diagnosis, treatment and management of melanoma during their long and remarkable careers.

“Their lifetime of achievements are truly remarkable and we are excited that they will share their wisdom at today’s event,” said MIA Conjoint Medical Director Professor Richard Scolyer. 

MIA Conjoint Medical Director Professor Georgina Long added, “Through their collective brilliance, they have not only cared for and changed the lives of many thousands of patients but they have also changed the way melanoma patients are managed worldwide.”

Individually and collectively, the five have made key discoveries and transformed global melanoma patient care, including the development of therapies, procedures and diagnostic tests that have become clinical practice worldwide, introducing novel treatments in patients with advanced melanoma and exploring targeted treatments and new immunotherapies.

In addition to hearing from the luminaries, renowned surgical oncologist from the MD Anderson Cancer Center in the US, Professor Jeffrey Gershenwald, is also presenting at the symposium on the future of melanoma prognosis and staging.

The other speakers at the event, all MIA clinicians/researchers, will round out the program presenting on a range of topics including the causes, prevention and diagnosis of melanoma as well as giving promising updates on the latest treatments for early and advanced melanoma.

“Through this symposium, we are bringing together the country’s best melanoma specialists to collaborate and share knowledge. This truly is the ultimate masterclass in melanoma,” Professors Scolyer and Long added.


The Celebrated Luminaries

  • Professor John Thompson AO has long been a world leader in melanoma research. He pioneered the novel technique of isolated limb infusion with cytotoxic agents for melanoma, a simpler, less costly form of treatment than conventional isolated limb perfusion, but one that is equally effective. A former liver transplant surgeon, Professor Thompson is the author of more than 700 peer-reviewed articles. He stepped down as Executive Director of MIA in 2016 after 18 years in the position and plans to retire from clinical work at the end of this year.
  • Professor Richard Kefford AM’s research has played a seminal role in revealing the genetics of melanoma. He has authored more than 300 journal publications, chapters and books. He has been an investigator on more than 50 clinical trials including many that explore new immunotherapies to modify the actions of the immune system. He was named Outstanding Cancer Researcher of the Year in the 2017 Cancer Institute NSW Premier Awards. Professor Kefford is winding down his clinical work although he will continue his research projects for a few more years.
  • Nuclear medicine physician Professor Roger Uren is renowned for the development of lymphatic mapping in the management of patients with melanoma. His pioneering use of lymphoscintigraphy shed important new light on lymphatic drainage pathways and was adopted worldwide. He recently retired from clinical practice.
  • Professor Peter Hersey is recognised as a pioneer of immunotherapy for melanoma in Australia and in focusing on properties of melanoma cells that make them resistant to therapies.  He has authored over 340 peer reviewed publications on melanoma and has been involved in conduct of over 50 clinical trials in melanoma. He has finished up clinical practice but continues to conduct research in the twilight of his career.
  • Known as the “guru” of pathology in Australia, Professor Stan McCarthy AO has dedicated more than 50 years to the public health system as a senior staff specialist and histopathologist, firstly at Sydney Hospital and later at Royal Prince Alfred Hospital. He is considered a world authority on melanoma pathology and although he retired in January 2018, he will continue to lend his considerable expertise to difficult cases into the future.
Kyly Clarke urges Aussies to step up to save lives from melanoma
03 Feb 2020

Kyly Clarke urges Aussies to step up to save lives from melanoma

Australian television presenter, interior designer and mother Kyly Clarke has been announced as the new Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign Melanoma March.

Improving support for our patients across Australia.
03 Feb 2020

Improving support for our patients across Australia.

Melanoma Institute Australia has recently partnered with three other organisations to boost support for melanoma patients and their carers across Australia.   

Boost to melanoma support in WA
31 Jan 2020

Boost to melanoma support in WA

Melanoma patients and their families across Western Australia will benefit from strengthened and expanded services with the merging of melanomaWA and Melanoma Institute Australia.

New Test to Predict Primary Melanoma Progression
21 Jan 2020

New Test to Predict Primary Melanoma Progression

Australian researchers have played a critical role in the discovery of a potential new test to predict which early stage melanoma patients are at high risk of their disease recurring and progressing.

Community Fundraising December Wrap-Up
14 Jan 2020

Community Fundraising December Wrap-Up

We are extremely grateful for our community fundraisers, who, even in this difficult time, have given up their time and effort to fundraise so we can continue to work towards our goal of zero deaths from melanoma.

Two melanoma treatments approved for PBS listing
24 Dec 2019

Two melanoma treatments approved for PBS listing

Melanoma patients are set to benefit from subsidised access to immunotherapy treatment for high risk early-stage and advanced-stage melanoma patients.    

Immunotherapy: the decade's biggest health advance
23 Dec 2019

Immunotherapy: the decade's biggest health advance

An informative article on how immunotherapy is revolutionising cancer treatment, written by Jill Margo and featured in the Australian Financial Review.  

 

Boost to Melanoma Services in the Riverina
12 Dec 2019

Boost to Melanoma Services in the Riverina

Melanoma patients and their families in the Riverina will benefit from strengthened and sustained melanoma services with the merger of the Amie St Clair Melanoma Trust and Melanoma Institute Australia.

Winner of the SunSafe Student Ambassador Program announced
11 Dec 2019

Winner of the SunSafe Student Ambassador Program announced

Belmont High School at Lake Macquarie has been announced winner of the 2019 SunSafe Student Ambassador Program video competition.

Community Fundraising November Wrap-Up
04 Dec 2019

Community Fundraising November Wrap-Up

It’s time again to say thank you to our amazing community fundraisers!

MIA & MPA Patient Information Evening videos now available
03 Dec 2019

MIA & MPA Patient Information Evening videos now available

Videos of the sessions at the recent Patient Information Evening co-hosted by Melanoma Institute Australia (MIA) and Melanoma Patients Australia (MPA) are now available for viewing.

MIA shines in poster session
22 Nov 2019

MIA shines in poster session

MIA is well-represented in the poster sessions at the Society for Melanoma Research 2019 Congress in the USA, with four poster presentations being given by members of our translational research lab.

MIA Co-Medical Director opens SMR Congress in USA
21 Nov 2019

MIA Co-Medical Director opens SMR Congress in USA

Professor Georgina Long has today opened the Society for Melanoma Research 2019 Congress in Salt Lake City, Utah.

Highly Cited Researchers List names MIA Co-Medical Directors
20 Nov 2019

Highly Cited Researchers List names MIA Co-Medical Directors

MIA’s Co-Medical Directors, Professor Georgina Long and Professor Richard Scolyer, have both been named Highly Cited Researchers, according to the Clarivate Analytics Highly Cited Researchers 2019 list.

MPA and MIA collaboration
07 Nov 2019

MPA and MIA collaboration

Melanoma Patients Australia (MPA) and Melanoma Institute Australia (MIA) have announced a new multi-year agreement to provide enhanced support services for melanoma patients nationally.

Community Fundraising October Wrap-Up
04 Nov 2019

Community Fundraising October Wrap-Up

It is time again to say thank you to our incredible community fundraisers who are helping us get closer to our goal of zero deaths from melanoma.

Promising data for advanced melanoma patients
09 Oct 2019

Promising data for advanced melanoma patients

MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.

Melanoma Information Forum
04 Oct 2019

Melanoma Information Forum

We are delighted to partner with Melanoma Patients Australia to host a Melanoma Information Forum at The Poche Centre on 6th November.

Community Fundraising September Wrap-Up
02 Oct 2019

Community Fundraising September Wrap-Up

Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.

Notice for Supporters to Submit to PBAC
26 Sep 2019

Notice for Supporters to Submit to PBAC

Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.